The PD-L1 Biomarker Testing Market offers opportunities driven by the rising incidence of non-small cell lung cancer and the ...
NORTHFIELD, Ill.--(BUSINESS WIRE)--The College of American Pathologists (CAP) in collaboration with the International Association for the Study of Lung Cancer (IASLC), Pulmonary Pathology Society (PPS ...
Creatv Bio, a Division of Creatv MicroTech, Inc. ("Creatv") has announced the initiation of a collaboration with CytoDyn Inc. of Vancouver, Washington ("CytoDyn") to provide its' LifeTracDx® liquid ...
Jonathan Thompson, MD, MS, emphasized that comprehensive biomarker testing with next-generation sequencing and PD-L1 analysis—implemented as reflex testing at biopsy—is essential to guide precision ...
A newly discovered cancer trick that weakens immunotherapy may be stopped by everyday statins.
GUILDFORD, UK / ACCESSWIRE / November 9, 2023 / ANGLE plc (AIM:AGL)(OTCQX:ANPCY), a world-leading liquid biopsy company with innovative circulating tumour cell (CTC) diagnostic solutions for use in ...
Two viewpoint articles published in JAMA Oncology provide opposing opinions on the benefit of testing for programmed death-ligand 1 (PD-L1) expression in patients with non-small-cell lung cancer ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results